Most Read Articles
2 days ago
There appears to be no association between aortic pulse wave velocity, a measure of vascular stiffness, and migraine, as reported in a recent study.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
3 days ago
The dietary intake of gluten does not appear to be a risk factor for psoriasis, psoriatic arthritis or atopic dermatitis in women, reports a new study.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

TLR4 blockade in rheumatoid arthritis disappoints in phase II trial

11 Feb 2020

Blocking the toll-like receptor (TLR) 4 pathway with NI-0101, a first-in-class humanized monoclonal antibody, has failed to improve disease parameters in rheumatoid arthritis (RA) in a phase II trial.

The trial randomized 90 ACPA-positive RA patients with inadequate response to methotrexate to receive either NI-0101 (5 mg/kg every 2 weeks; n=61) or placebo (n=29) for 12 weeks. Of these, 86 completed the study.

Researchers evaluated treatment effect on the following measures: Disease Activity Score (28-joint count) with C reactive protein (DAS28-CRP), European League Against Rheumatism (EULAR) good and moderate responses, and American College of Rheumatology (ACR) 20, ACR50 and ACR70 responses. They conducted subgroup analyses defined by biomarkers and reported safety.

Efficacy endpoints did not significantly differ between the active and placebo treatment groups. In subgroup analyses that used baseline parameters as covariants, no patient population particularly benefitted from NI-0101.

The incidence of treatment-emergent adverse events was similar in the two treatment groups, recorded in 51.7 percent of patients on placebo and in 52.5 percent of those on NI-0101.

The present data show that blocking the TLR4 pathway alone does not produce improvements in RA, according to the researchers. Broader and/or earlier inhibitory approaches may be needed for successful targeting of innate immune pathways in RA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
There appears to be no association between aortic pulse wave velocity, a measure of vascular stiffness, and migraine, as reported in a recent study.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
3 days ago
The dietary intake of gluten does not appear to be a risk factor for psoriasis, psoriatic arthritis or atopic dermatitis in women, reports a new study.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.